Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
03 Maio 2023 - 8:00AM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that Sean Cassidy, Chief Financial
Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate
and Business Development, will participate in a fireside chat at
the Bank of America Securities 2023 Healthcare Conference on
Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m. PT in Las Vegas.
A live audio webcast of the presentation will be
available here and under “Events and Presentations” of
the Investors and Media section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC®
protein degraders against validated and “undruggable” targets, the
company has three investigational clinical-stage programs:
bavdegalutamide (ARV-110) and ARV-766 for the treatment of men with
metastatic castration-resistant prostate cancer; and vepdegestrant
(ARV-471) for the treatment of patients with early and locally
advanced or metastatic ER positive/human epidermal growth factor
receptor 2 (HER2) negative (ER+/HER2-) breast cancer. For more
information, visit www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kirsten Owens+1 (203)
584-0307Kirsten.Owens@arvinas.com
Arvinas (NASDAQ:ARVN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Arvinas (NASDAQ:ARVN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024